|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5453269A
(en)
|
1986-04-14 |
1995-09-26 |
The General Hospital Corporation |
Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5559212A
(en)
|
1988-04-06 |
1996-09-24 |
Alfacell Corporation |
Frog embryo and egg-derived tumor cell anti-proliferation protein
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5840840A
(en)
|
1990-04-17 |
1998-11-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selective RNase cytotoxic reagents
|
|
ES2133285T3
(es)
|
1991-04-17 |
1999-09-16 |
Medisup Int Nv |
Polipeptidos hidrosolubles que tienen una alta afinidad para los interferones alfa y beta.
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
GB9300686D0
(en)
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6348343B2
(en)
|
1995-02-24 |
2002-02-19 |
Genentech, Inc. |
Human DNase I variants
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
US6482626B2
(en)
|
1996-02-05 |
2002-11-19 |
Genentech, Inc. |
Human DNase
|
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
|
ES2300113T3
(es)
|
1996-08-02 |
2008-06-01 |
Bristol-Myers Squibb Company |
Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
ES2191827T3
(es)
|
1996-10-17 |
2003-09-16 |
Immunomedics Inc |
Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US20030054359A1
(en)
|
1997-06-16 |
2003-03-20 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20020192659A1
(en)
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US5840296A
(en)
|
1997-10-15 |
1998-11-24 |
Raines; Ronald T. |
Engineered cytotoxic ribonuclease A
|
|
US6280991B1
(en)
|
1997-10-15 |
2001-08-28 |
Wisconsin Alumni Research Foundation |
Engineered cytotoxic ribonclease
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
WO2000009560A2
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6239257B1
(en)
|
1998-12-30 |
2001-05-29 |
Alfacell Corporation |
Family of proteins belonging to the pancreatic ribonuclease a superfamily
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
EP1194451A1
(en)
|
1999-07-02 |
2002-04-10 |
Genentech, Inc. |
Fusion peptides comprising a peptide ligand domain and a multimerization domain
|
|
US6175003B1
(en)
|
1999-09-10 |
2001-01-16 |
Alfacell Corporation |
Nucleic acids encoding ribonucleases and methods of making them
|
|
AU1084901A
(en)
|
1999-10-14 |
2001-04-23 |
Martha S. Hayden-Ledbetter |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
|
NZ545176A
(en)
|
2001-01-29 |
2008-05-30 |
Biogen Idec Inc |
Modified antibodies reactive with CD20 and methods of use
|
|
CN1330664C
(zh)
|
2001-03-07 |
2007-08-08 |
默克专利有限公司 |
用于含杂合同种型抗体部分的蛋白质的表达技术
|
|
JP4586310B2
(ja)
|
2001-07-04 |
2010-11-24 |
株式会社Ihi |
セラミックス複合部材の製造方法
|
|
US20060040262A1
(en)
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2489446A1
(en)
|
2002-06-14 |
2003-12-24 |
Wisconsin Alumni Research Foundation |
Ribonuclease zymogen design
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
JP2006515747A
(ja)
|
2002-11-01 |
2006-06-08 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US7067298B2
(en)
|
2003-03-31 |
2006-06-27 |
Ambion, Inc. |
Compositions and methods of using a synthetic Dnase I
|
|
US7666417B2
(en)
*
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
EP2502935B1
(en)
|
2003-08-22 |
2017-03-29 |
Biogen MA Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
WO2005063815A2
(en)
*
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
BRPI0417916A
(pt)
|
2003-12-31 |
2007-04-10 |
Merck Patent Gmbh |
proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
AU2005214361B2
(en)
|
2004-02-13 |
2011-03-24 |
Immunomedics, Inc. |
Fusion proteins containing recombinant cytotoxic RNAses
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Ｆｃ変異体
|
|
RU2007108538A
(ru)
|
2004-08-11 |
2008-09-20 |
Трабьон Фармасьютикалз, Инк. (Us) |
Слитые со связывающим доменом белки
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
DE102005000921A1
(de)
|
2005-01-07 |
2006-07-27 |
Siemens Ag |
Verfahren und Vorrichtung zur Broadband-Datenverteilung zwischen mehreren Benutzerendgeräten
|
|
DE102005009219A1
(de)
|
2005-02-25 |
2006-08-31 |
Martin-Luther-Universität Halle-Wittenberg |
Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
|
|
WO2006105062A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Verenium Corporation |
Altered antibody fc regions and uses thereof
|
|
EP1888649A2
(en)
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
EP1896579A2
(en)
|
2005-06-16 |
2008-03-12 |
Wisconsin Alumni Research Foundation |
Cytotoxic ribonuclease variants
|
|
JP5114392B2
(ja)
|
2005-06-16 |
2013-01-09 |
ウイスコンシン アラムニ リサーチ ファンデーション |
細胞傷害性リボヌクレアーゼ変異株
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
JP4860702B2
(ja)
|
2005-10-21 |
2012-01-25 |
エフ．ホフマン−ラ ロシュ アーゲー |
ポリペプチドのリコンビナント発現のための方法
|
|
BRPI0710011A2
(pt)
|
2006-04-14 |
2011-08-02 |
Trubion Pharmaceuticals Inc |
proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
|
|
WO2007122511A2
(en)
|
2006-04-21 |
2007-11-01 |
Mab-Factory Gmbh |
Antibody-rnase-conjugate
|
|
GB0611444D0
(en)
|
2006-06-09 |
2006-07-19 |
Medical Res Council Technology |
Rnase H2 complex and genes therefor
|
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
|
EP1905841A1
(en)
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
|
EP2144930A1
(en)
*
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
CN101842389A
(zh)
|
2007-06-12 |
2010-09-22 |
惠氏有限责任公司 |
抗cd20治疗组合物和方法
|
|
WO2009023386A2
(en)
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
WO2009012600A1
(en)
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
|
EP2220125A4
(en)
|
2007-11-13 |
2010-12-29 |
Sapphire Energy Inc |
PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
JP2012503985A
(ja)
*
|
2008-09-26 |
2012-02-16 |
ジェネンテック， インコーポレイテッド |
ループスの治療、診断、モニタリング方法
|
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
DK3202898T3
(en)
*
|
2009-11-02 |
2019-01-14 |
Univ Washington |
THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
|
|
TWI529163B
(zh)
|
2011-01-25 |
2016-04-11 |
陶氏農業科學公司 |
用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
|
|
AU2012220861A1
(en)
|
2011-02-23 |
2013-09-05 |
Amgen Inc. |
Cell culture media for UVC exposure and methods related thereto
|
|
MX363013B
(es)
|
2011-02-25 |
2019-03-04 |
Recombinetics Inc |
Animales genéticamente modificados y métodos para su obtención.
|
|
KR102055331B1
(ko)
|
2011-04-21 |
2019-12-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
B형 간염 바이러스(hbv) 발현 조절
|
|
AU2012249360B2
(en)
|
2011-04-29 |
2015-12-24 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
|
US20140178479A1
(en)
|
2011-08-12 |
2014-06-26 |
Perosphere, Inc. |
Concentrated Felbamate Formulations for Parenteral Administration
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
WO2015066550A1
(en)
|
2013-10-31 |
2015-05-07 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
US20190241878A1
(en)
|
2016-07-01 |
2019-08-08 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|